print back
Bioindustry Park Silvano Fumero S.p.A.

Bioindustry Park, a science park with bioindustrial and biotechnological aims, promotes and supports research in the field of Life Sciences. The Park acts as a link between university research and the corporate world, which is intended to stimulate the foundation and growth of innovative companies. In addition, the Park offers possibilities for branch offices, research laboratories and special consulting, such as firm check-ups, feasibility studies and technology transfer

Do you want to print an overview or a detailed profile?

Adress

Via Ribes, 5
10015 Colleretto Giacosa - Turin
(Piedmont)

Telephone

+39 0125 561311

Fax

+39 0125 538350

World Wide Web

www.bioindustrypark.eu

 


Research and Development

Ovarian Cancer project

Description

“New potential targets for diagnosis and therapy of cisplatin resistant ovarian cancer.” Patent pending. Diagnosis
The usual treatment of ovarian cancer carcinoma is the cytoreductive surgery followed by the use of a first line chemotherapeutics agent (platinum + taxanes) and a second line agent (topotecan, ifosfamide). The problem is that 30% of patients are resistant to the first line agent and consequently this also decreases the efficacy of the second one. The goal of the invention is to prevent the use of platinum drugs in platinum-resistant patients by developing a resistance diagnostic kit.

Breast Cancer project

Description

“Use of ER-? derived peptides that restore sensibility to anti-estrogenic compounds in breast cancer cells.” Patent pending. Therapy: Estrogen receptors ER? is over-expressed in 70% of breast cancer cases. This over-expression causes tumorigenesis because of the excessive number of estrogen (E2) that binds to ER?
The usual treatment is the endocrine therapy that involves selective estrogen receptor modulators (SERM) such as tamoxifen which behaves as E2 antagonist in breast tissue. Unfortunately, the majority of initially responsive patients builds up resistance to anti-estrogens.
Resistance mechanisms to tamoxifen were investigated and the delocalization of an ER? co-repression complex seems to occur. This delocalization is due to its specific interaction with a protein that recognizes its nuclear export sequence (NES).

Aim

The aim of the invention was to restore the sensibility of breast cancer cells line to anti-estrogens by providing a mimic peptide able to block the interaction between the ER? co-repression complex and this specific protein.

Amyotrophic Lateral Sclerosis project

Description

“Biomarkers for diagnosis and progression of neurodegenerative diseases, in particular ALS.” Patent Pending. Diagnosis
ALS is a rapidly progressive devastating disease for which the only therapy available is rizuole. The diagnosis is clinical and candidate disease biomarkers have not yet been found, whereas they are crucial for the early diagnosis and cure of this disease.

Aim

The aim of the project was to identify qualitative and quantitative modifications of plasma proteome in ALS-affected patients in comparison with inflamed and not-inflamed controls. They discovered 9 biomarkers, among them one where the expression level changes during the progression of the disease from the onset, enabling the inventors to follow the disease quantitatively.